Timken Co. (TKR) Tops Q1 EPS Views; Boosts FY12 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts TKR Hot Sheet
Price: $109.33 +0.86%
Revenue Growth %: +4.3%
Financial Fact:
Impairment and restructuring charges: 5.3M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +4.3%
Financial Fact:
Impairment and restructuring charges: 5.3M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Timken Co. (NYSE: TKR) reported Q1 EPS of $1.58, $0.33 better than the analyst estimate of $1.25. Revenue for the quarter came in at $1.4 billion versus the consensus estimate of $1.37 billion.
Timken Co. sees FY2012 EPS of $5.40-$5.70, versus the consensus of $5.28. Timken now expects sales growth of 7 to 10 percent in 2012.
For earnings history and earnings-related data on Timken Co. (TKR) click here.
Timken Co. sees FY2012 EPS of $5.40-$5.70, versus the consensus of $5.28. Timken now expects sales growth of 7 to 10 percent in 2012.
For earnings history and earnings-related data on Timken Co. (TKR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Bristol Myers Squibb MS CAR T therapy data shows patients off DMTs
- Pfizer's 25-valent pneumococcal vaccine shows Phase 2 results
Create E-mail Alert Related Categories
Earnings, Guidance, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
